VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager program through a collaboration with ATUM. The partnership will leverage ATUM's Leap-In Transposase(R) technology to generate stable clonal cell lines that support IND/CTA-enabling activities and future clinical development. This milestone follows encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting and is intended to support CMC development, including early process, analytical, and formulation development, as well as the production of material for nonclinical studies.
VERAXA's BiTAC-TCE platform is designed to improve tumor selectivity by splitting the T-cell engager into two complementary precursors that activate only when both bind separate tumor targets on the same cell. The company believes this conditional "AND"-gated approach could reduce off-tumor toxicity associated with conventional T-cell engagers while maintaining anti-cancer activity, potentially enabling higher dosing and a broader therapeutic window. This innovative design addresses a key challenge in cancer immunotherapy: the balance between efficacy and safety.
The initiation of cell line development marks a critical step in advancing the BiTAC program toward clinical trials. By partnering with ATUM, VERAXA aims to accelerate the production of high-quality cell lines that are essential for reproducible manufacturing and regulatory submissions. The collaboration encompasses early process development, analytical methods, and formulation strategies, laying the groundwork for future clinical studies. The company's forward-looking statements highlight the potential of this approach to transform cancer treatment, though they also caution about inherent risks and uncertainties.
For more details, the full press release is available at https://ibn.fm/FCIlk. Additional information about VERAXA and its pipeline can be found in the company's newsroom at https://ibn.fm/VRXA.
